Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1807156

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1807156

India Cancer Diagnostics Market By Product, By Type, By Application, By Test-Type, By End-User, By Region, Competition, Forecast, & Opportunities, 2020-2030F

PUBLISHED:
PAGES: 85 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 3500
PDF and Excel (Multi-User License)
USD 4500
PDF and Excel (Custom Research License)
USD 7000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

India Cancer Diagnostics Market was valued at USD 4.56 billion in 2024 and is expected to reach USD 8.12 billion by 2030, growing with a CAGR of 10.21% in the forecast period. The cancer diagnostics market in India is experiencing robust growth, driven by a combination of lifestyle changes, increasing health awareness, and advancements in healthcare infrastructure. As individuals become more conscious of their well-being, there is a rising focus on early detection and preventive healthcare. The growing prevalence of cancer, coupled with a heightened emphasis on timely diagnosis, is encouraging the adoption of sophisticated diagnostic tools across the country. Modern lifestyles, marked by high stress and limited time for regular health checkups, often lead to delays in disease detection. This has increased the demand for accurate and accessible diagnostic solutions that can identify cancer at an early stage. As a result, more people are turning to specialized cancer diagnostics to ensure effective monitoring of their health, especially as early diagnosis significantly improves treatment outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.56 Billion
Market Size 2030USD 8.12 Billion
CAGR 2025-203010.21%
Fastest Growing SegmentConsumables
Largest MarketNorth India

In addition, rising healthcare expenditure and ongoing investments in medical technologies are further propelling the market forward. The expanding network of diagnostic laboratories and the integration of advanced techniques such as molecular diagnostics, imaging, and biomarker testing are also enhancing the scope of cancer detection. India's aging population is playing a crucial role in driving demand. Older adults are more susceptible to chronic conditions like cancer, and they increasingly rely on reliable diagnostic services to manage their health proactively. The Indian cancer diagnostics market is poised for significant expansion, supported by a blend of technological innovation, demographic shifts, and a growing culture of health consciousness.

Key Market Drivers

Increasing Cancer Incidence

India has witnessed a rising incidence of cancer, partly due to lifestyle factors, environmental pollution, and an aging population. India's population has been steadily growing, and with it, the proportion of elderly individuals. Aging is a well-known risk factor for cancer, as cellular changes over time can increase the likelihood of malignancies. This demographic shift has contributed to the increased cancer burden in the country. For instance, in May 2025, a report by the National Academy of Medical Sciences (NAMS) highlighted that inadequate diagnostic services remained a critical gap in cancer care in India. It stated that patients in India often presented with later-stage disease compared to those in Western countries. The report also noted that nearly 200,000 new cancer cases were reported annually, underscoring the urgent need for improved early detection and diagnostic infrastructure.

Urbanization and the adoption of Western lifestyles have brought about significant changes in dietary habits and physical activity levels among Indians. Diets high in processed foods, low in fruits and vegetables, and sedentary lifestyles are associated with higher cancer risk. The prevalence of these factors has contributed to the rising cancer incidence. Environmental pollution, exposure to carcinogens, and industrialization have led to increased cancer risk. Pollutants such as air pollutants, pesticides, and chemicals in groundwater can contribute to the development of cancer. As industrialization continues, these environmental factors become more pronounced. A lack of awareness about cancer symptoms and the importance of regular screenings has delayed diagnoses in many cases. Late-stage cancer diagnoses often result in more aggressive treatment and poorer outcomes. As awareness campaigns increase, more individuals are seeking early detection, which is a positive step toward mitigating the impact of cancer.

The escalating cancer incidence in India has profound implications for the cancer diagnostics market in the country. With more individuals at risk of cancer, there is a growing demand for diagnostic services. This includes screening tests, imaging studies, and laboratory diagnostics. Healthcare providers are investing in advanced diagnostic technologies to meet this demand. To keep pace with the rising cancer burden, there have been significant advancements in diagnostic technologies. From state-of-the-art imaging modalities to molecular diagnostics, these innovations aid in early detection and precise diagnosis, improving patient outcomes. The surge in cancer incidence has prompted increased investments in cancer research and development in India. This includes the development of new diagnostic tests, therapies, and treatment modalities. As a result, the cancer diagnostics market is becoming more robust and competitive. The increasing cancer incidence in India presents substantial growth opportunities for companies operating in the cancer diagnostics sector. Market players are expanding their portfolios, collaborating with research institutions, and enhancing their presence to cater to the growing demand for diagnostic solutions.

Key Market Challenges

Limited Healthcare Infrastructure

One of the primary challenges in the growth of the India Cancer Diagnostics Market is the limited healthcare infrastructure, especially in rural and underserved areas. While major cities have advanced diagnostic facilities, a significant portion of the population in remote regions lacks access to even basic healthcare services, including cancer diagnostics.

The lack of infrastructure restricts the reach of cancer diagnostic services. Patients in rural areas may face long travel distances and high costs to access diagnostic centers in urban areas. This hinders early detection and timely treatment, ultimately impacting market growth. Government initiatives to expand healthcare infrastructure, particularly in rural areas, can help mitigate this challenge. Investments in building diagnostic centers, telemedicine services, and mobile clinics can extend the reach of cancer diagnostics to underserved populations.

Key Market Trends

Rise in Personalized Medicine and Targeted Therapies

Personalized medicine and targeted therapies have gained prominence in cancer diagnostics and treatment. Advancements in molecular diagnostics and genomic profiling have allowed healthcare providers to tailor cancer therapies to the specific genetic characteristics of a patient's tumor. This trend is increasingly shaping the landscape of cancer diagnostics in India.

The adoption of personalized medicine not only improves treatment outcomes but also drives the demand for advanced diagnostic tests that identify specific biomarkers and genetic mutations. Diagnostic companies are developing tests that help oncologists select the most effective treatments for individual patients, leading to increased market growth. Liquid biopsies, which detect circulating tumor DNA, are gaining traction for monitoring treatment response and identifying resistance mutations. The companion diagnostics are becoming more common, guiding the use of targeted therapies.

Key Market Players

  • Baxter Pharmaceuticals India Private Limited.
  • Bristol-Myers Squibb India Private Limited.
  • Cipla Ltd.
  • Roche Products (India) Private Limited.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd
  • Abbott India Laboratories Limited
  • BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
  • Siemens Healthcare Private Limited.
  • Thermo Fisher Scientific India Private Limited.

Report Scope:

In this report, the India Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

India Cancer Diagnostics Market, By Product:

  • Instruments
  • Consumables
  • Services

India Cancer Diagnostics Market, By Type:

  • IVD
  • LDT
  • Imaging

India Cancer Diagnostics Market, By Application:

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

India Cancer Diagnostics Market, By Test-Type:

  • Biopsy
  • Others

India Cancer Diagnostics Market, By End-User:

  • Hospitals
  • Laboratories
  • Others

India Cancer Diagnostics Market, By Region:

  • North India
  • South India
  • East India
  • West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Cancer Diagnostics Market.

Available Customizations:

India Cancer Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 18914

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Applications
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. India Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Consumables, Services)
    • 5.2.2. By Type (IVD, LDT, Imaging)
    • 5.2.3. By Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others)
    • 5.2.4. By Test-Type (Biopsy, Others)
    • 5.2.5. By End-User (Hospitals, Laboratories, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North India Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By Test-Type
    • 6.2.5. By End-User

7. South India Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By Test-Type
    • 7.2.5. By End-User

8. East India Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By Test-Type
    • 8.2.5. By End-User

9. West India Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By Test-Type
    • 9.2.5. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. India Cancer Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Baxter Pharmaceuticals India Private Limited
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Bristol-Myers Squibb India Private Limited.
  • 14.3. Cipla Ltd.
  • 14.4. Roche Products (India) Private Limited.
  • 14.5. Glenmark Pharmaceuticals Ltd.
  • 14.6. Lupin Ltd
  • 14.7. Abbott India Laboratories Limited
  • 14.8. BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
  • 14.9. Siemens Healthcare Private Limited.
  • 14.10. Thermo Fisher Scientific India Private Limited.

15. Strategic Recommendations

16. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!